BTIG Raises Abivax Price Target to $150, Maintains Buy Rating
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Source: Benzinga
- Price Target Increase: BTIG raised the price target for Abivax SA from $120 to $150 while maintaining a Buy rating, reflecting confidence in the company's future growth potential.
- Market Performance: Abivax shares closed at $126.48 on Wednesday, indicating a positive market response that may attract more investor interest.
- Rating Changes: Cantor Fitzgerald increased the price target for Alphabet Inc from $310 to $370 and upgraded the stock from Neutral to Overweight, signaling optimism about its future performance.
- Stock Dynamics: Alphabet shares closed at $322.03 on Wednesday, reflecting market recognition of its growth prospects, which could drive more capital into the stock.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on ABVX
Wall Street analysts forecast ABVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVX is 153.88 USD with a low forecast of 131.00 USD and a high forecast of 176.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 113.980
Low
131.00
Averages
153.88
High
176.00
Current: 113.980
Low
131.00
Averages
153.88
High
176.00
About ABVX
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Denies Acquisition Talks with Abivax, CEO Reaffirms No Negotiations
- Acquisition Rumor Denial: Abivax CEO Marc de Garidel emphasized that no acquisition discussions with Eli Lilly took place, asserting that such conversations would be illegal, demonstrating the company's firm stance against external distractions.
- Stock Price Surge Context: Abivax's shares have skyrocketed over 1,700% in the past 12 months, primarily driven by acquisition rumors and promising clinical trial data for its lead asset, obefazimod, against ulcerative colitis, reflecting strong market interest in its future potential.
- Government Engagement Requirement: De Garidel pointed out that any foreign acquisition must first involve public transaction communication with the French government, which has not occurred, further confirming the falsehood of the acquisition rumors.
- Focus on Core Business: Despite the acquisition rumors generating market attention, De Garidel stressed that the company will concentrate on its core operations, avoiding distractions from external noise to ensure continued progress in its R&D and market strategies.
Continue Reading
Abivax (ABVX) Acquisition Potential Could Boost Shares by 72%
- Drug Development Progress: Abivax's leading drug candidate, obefazimod, has shown significant efficacy in clinical trials, with 47.3% of patients having inadequate responses to prior therapies, indicating its potential to outperform existing drugs in the ulcerative colitis market.
- Market Valuation Surge: Currently valued at €8.74 billion (approximately $10.15 billion), Abivax is reportedly targeted for a €15 billion ($17.42 billion) acquisition by Eli Lilly, representing a 72% premium, highlighting its attractiveness in the biopharmaceutical sector.
- Competitive Advantage Emergence: The unique mechanism of obefazimod allows it to control ulcerative colitis symptoms without compromising the immune system, potentially attracting a broader patient population and enhancing Abivax's market competitiveness.
- Investment Risks and Opportunities: While the prospects for obefazimod are promising, potential clinical or regulatory setbacks could impact stock prices, necessitating careful consideration of acquisition possibilities and their effects on share value.
Continue Reading